Dirigente medico I livello Pascale Dirigente medico I livello. e.simeone@istitutotumori.na.it

Transcript

1 CURRICULUM VITAE INFORMAZIONI PERSONALI Cognome Nome Simeone ester Data di nascita 27/01/1976 Qualifica Amministrazione Incarico attuale Dirigente medico I livello Pascale Dirigente medico I livello Numero telefonico dell ufficio Fax dell ufficio istituzionale e.simeone@istitutotumori.na.it TITOLO DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE Titolo di studio Altri titoli di studio e professionali Esperienze professionali (incarichi ricoperti) Laurea in Medicina e Chirurgia Specializzazione in Oncologia medica Contratti a progetto presso Codesto Istituto: Contratto di Collaborazione presso la Divisione di Immunologia dell Istituto Tumori di Napoli dal 16/12/2004 al Contratto di Collaborazione presso la Divisione di Oncologia Medica e Terapie Innovative del Dipartimento Melanoma, tessuti molli,muscolo-scheletrico, testacollo dell Istituto Tumori di Napoli dal //200 al 31/10/2009 Dirigente Medico di I livello dal 01/11/2009 presso la Divisione di Oncologia Medica e Terapie Innovative del Dipartimento Melanoma, tessuti molli,muscoloscheletrico, testa-collo dell Istituto Tumori di Napoli. Capacità linguistiche Capacità nell uso delle tecnologie Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare) Buona conoscenza dell Inglese buona Sub-investigator nei protocolli sperimentali sulla terapia del melanoma : Studio EORTC : Post-operative adjuvant Ganglioside GM2-KLH/QS- 21 vaccination treatment vs observation after resection of primary cutaneous melanoma (AJCC Stage II, T3-T4N0M0). A 2-arm multicenter randomized phase III trial. Studio EORTC : Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma Studio EORTC : Adjuvant Peg-Intron treatment in stage III melanoma. Peg-Intron versus observation after regional lymph node

2 dissection in AJCC stage III (TxN1-2Mo) melanoma patients. a randomized phase III trial Phase I and II Study on Pegylated Arginine Deiminase Treatment of subjects with metastatic melanoma A phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoma vaccine, Cancer Vax vaccine versus BCG plus a placebo as a post-surgical treatment for stage III-IV melanoma Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma : A randomized phase III study of the EORTC Melanoma Group A Multicenter Single arm Phase II of MDX-010 (BMS ) monotherapy in Patients with previously treated unresectable stage III or IV melanoma A phase III, open label, randomized, comparative study of CP-675,206 and either Dacarbazine or Temozolomide in patients with advanced melanoma Studio multicentrico randomizzato in doppio cieco a 2 bracci di fase III su pazienti affetti da melanoma non trattato metastatico, trattati con dacarbazina più ipilimumab (MDX-010) vs dacarbazina più placebo Adjuvant immunotherapy with anti-ctla-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high risk stage III melanoma : A randomized, double-blind phase III trial of the EORTC Melanoma Group A randomized, multi-dose, open label, phase II Study of BMS as a second line monotherapy in subjects with previously treated unresectable stage III or IV melanoma A phase III, open label, randomized, comparative study of Allovectin 7 versus dacarbazine or temozolomide in patients with unresectable cutaneous- sub cutaneous stage III melanoma A Double-blind, randomized, placebo- controlled phase III study with recmage-a3+as15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

3 An open randomized phase III study with NO25026 vs dacarbazine in metastatic melanoma S. Scala, A. Ottaiano, P.A. Ascierto, M. Cavalli, E. Simeone, P. Giuliano, M. Napolitano, R. Franco, G. Botti, G. Castello Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res Mar 1;11(5): De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia, Di Martino N, Ciardiello F, Catalano G, Bianco AR. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer May 9;92(9): A Daponte, PA Ascierto, A Gravina, MT Melucci, S Scala, A Ottaiano, E Simeone, G Palmieri, G Comella TEMOZOLOMIDE AND CISPLATIN IN AVDANCED MALIGNANT MELANOMA Anticancer Res Mar-Apr;25(2B): Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol Oct 20;23(30): Ascierto PA, Scala S, Ottaiano A, Simeone E, de Michele I, Palmieri G, Castello G. Adjuvant treatment of malignant melanoma: Where are we? Crit Rev Oncol Hematol Jun 27

4 Stanganelli I, Brucale A, Calori L, Gori R, Lovato A, Magi S, Kopf B, Bacchilega R, Rapisarda V, Testori A, Ascierto PA, Simeone E, Ferri M. Computer-aided Diagnosis of Melanocytic Lesions Anticancer Research 25 : , 2005 Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napoletano M, Ottaiano A, Lombardi ML, Luongo M, Simeone E, Pastiglia D, Mauro F, De Michele I, Calemma R, Botti G, Caracò C, Nicoletti G, Satriano RA, Castello G Human melanoma metastases express functional CXCR4 Clin Cancer Res 2006, Apr 15; 12(8) : Milena Casula, Maria Colombino, Maria P. Satta, Antonio Cossu, Amelia Lissia, Mario Budroni, Ester Simeone, Rosa Calemma, Cinzia Loddo, Corrado Caracò, Nicola Mozzillo, Antonio Da ponte, Giuseppe Comella, Sergio Canzanella, Michele Guida, Giuseppe Castello, Paolo A. Ascierto, Giuseppe Palmieri. On behalf of the Italian melanoma Intergroup. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South of Italy. EJC 2007 Palmieri G, Satriano SM, Budroni M, Cossu A, Tanda F, Canzanella S, Caracò C, Simeone E, Da ponte A, Mozzillo N, Comella G, Castello G, Ascierto PA Serial detection of circulating tumour cells by riverse transcriptasepolymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma BMS Cancer Nov 15; 6: 266 Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, Bryce J, Caracò C, Satriano RA, Gianfranco N, Franco R, Botti G, Castello G Solubile interleukin 2 receptor in stage I-III melanoma Cytokine.2006 Feb 7; 33(3) : Fulciniti F, Ascierto PA, Simeone E, Bove P, Lo sito S, Russo S, Gallo MS, Greggi S Nevoid melanoma of the vagina : report of one case diagnosed on thin layer cytological preparations Cytojournal Jul 3; 4: 14 Ascierto PA, Simeone E, Palmieri G, Castello G Vaccines : What s news?

5 Int.J.Clin Invest Year XV, March 2007; 1: 1-4